Biofer Adds Allegation to Vifor Patent Fight on Injectafer Drug

Biofer SpA asked a federal court to let it add an allegation of induced infringement to its patent suit against Vifor Pharma AG over the active ingredient in Injectafer, American Regent’s injectable anemia treatment.

“Vifor is using its own sales force to promote third-party sales of Injectafer in the United States with full knowledge of Biofer’s infringement allegations,” Biofer said Tuesday in a motion to amend its complaint filed in the US District Court for the Eastern District of New York.

Switzerland-based Vifor manufactures the drug’s active ingredient, ferric carboxymaltose, and American Regent—a subsidiary of Tokyo-based Daiichi Sankyo Inc.—sells ...